| Literature DB >> 26854857 |
Alvin C Ma1,2, Melissa S McNulty1, Tanya L Poshusta1, Jarryd M Campbell1, Gabriel Martínez-Gálvez3, David P Argue1, Han B Lee1, Mark D Urban1, Cassandra E Bullard1, Patrick R Blackburn1, Toni K Man2, Karl J Clark1, Stephen C Ekker1.
Abstract
Transcription activator-like effectors (TALEs) are extremely effective, single-molecule DNA-targeting molecular cursors used for locus-specific genome science applications, including high-precision molecular medicine and other genome engineering applications. TALEs are used in genome engineering for locus-specific DNA editing and imaging, as artificial transcriptional activators and repressors, and for targeted epigenetic modification. TALEs as nucleases (TALENs) are effective editing tools and offer high binding specificity and fewer sequence constraints toward the targeted genome than other custom nuclease systems. One bottleneck of broader TALE use is reagent accessibility. For example, one commonly deployed method uses a multitube, 5-day assembly protocol. Here we describe FusX, a streamlined Golden Gate TALE assembly system that (1) is backward compatible with popular TALE backbones, (2) is functionalized as a single-tube 3-day TALE assembly process, (3) requires only commonly used basic molecular biology reagents, and (4) is cost-effective. More than 100 TALEN pairs have been successfully assembled using FusX, and 27 pairs were quantitatively tested in zebrafish, with each showing high somatic and germline activity. Furthermore, this assembly system is flexible and is compatible with standard molecular biology laboratory tools, but can be scaled with automated laboratory support. To demonstrate, we use a highly accessible and commercially available liquid-handling robot to rapidly and accurately assemble TALEs using the FusX TALE toolkit. Together, the FusX system accelerates TALE-based genomic science applications from basic science screening work for functional genomics testing and molecular medicine applications.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26854857 PMCID: PMC4931509 DOI: 10.1089/hum.2015.172
Source DB: PubMed Journal: Hum Gene Ther ISSN: 1043-0342 Impact factor: 5.695
Modification of tandem transcription activator-like effector intermediate vectors
| pFusX1* | pFus_A30A | N/A | N/A | N/A |
| pFusX2 | pFus_A30B | Short oligos | pFusX2-S: | |
| CCGGTGGTCTCTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCGAGACGT | ||||
| pFusX2-AS: CTCGCCATGGTCCTGGCACAGCACCGGCAACAGCCGCTGCACCGTTTCGAGCGCTTGCTTGCCGCCAGAGACCA | ||||
| pFusX3 | pFus_A30B | PCR | pFusX3-F: ATTCTTAAGCGTCTCCATGGCCTGACCCCG | |
| pFusX3-R: ATTGACGTCTCGCAGGCCATGGTCCTGG | ||||
| pFusX4 | pFus_A30B | PCR | pFusX4-F: GTTCTTAAGCGTCTCCCCTGACCCCG | |
| pFusX4-R: GTTGACGTCTCGGCCATGGTCCTGG |
Shown are restriction enzymes and sequences of short oligos or primers used in modification of pFus_A30B into pFusX2, pFusX3, and pFusX4. For pFusX2, annealed reverse complementary short oligos are used directly as the insert. For pFusX3 and pFusX4, PCR products from primers with pFus_A30B as template are used as inserts. No modification is needed for pFusX1, which is identical to pFus_A30B.
N/A, not applicable.
FusX system libraries required for constructing transcription activator-like effectors with 14.5, 15.5, and 16.5 repeats
Shown is detailed information including library names, plasmid quantities, description, and 5′ and 3′ overhang sequences (in boldface) produced by BsmBI digestion of the nine plasmid libraries required for making TALEs with 14.5 to 16.5 repeats. Compatible overhangs of destination vector with pFusX1 and pLR are boxed and underlined, respectively.
pLR, last half-repeat plasmid; RVD, repeat-variable diresidue; TALE, transcription activator-like effector; TALEN, TALE as nuclease.
Components used to build the FusX system: FusX# and Fus_B# libraries
Detailed information including plasmid names, plasmid quantities, description, and 5′ and 3′ overhang sequences (in boldface) produced by BsaI digestion of all the component plasmids used to synthesize FusX system libraries are listed. XX represents any of the four RVDs (HD, NG, NI, NN), and compatible overhangs with intermediate vectors are highlighted in the same styles.
RVD, repeat-variable diresidue.

Construction of the FusX1–4 libraries. (A) Component plasmids used to construct the pFusX1–4 libraries. pXX-1 and pXX-10 are single-RVD (repeat-variable diresidue) encoding plasmids from the original Golden Gate system (2.0)[16]; pXX-M and -MM are new, single RVD modules with designated sequence and BsaI overhangs for ligation in between pXX-1 and pXX-10 to form 3-mer intermediates in pFusX1–4 libraries. pXX-MM includes extra silent mutations and is used only to construct the pFusX3 library, providing a specific primer-binding site for sequencing of long TALE (transcription activator-like effector) domain. “XX” represents any of the four RVD modules: HD, NG, NI, NN. (B) Schematic diagram showing sequential ligation of single RVD component plasmids into the four intermediate vectors: pFusX1, pFusX2, pFusX3, pFusX4. Dotted arrows indicate ligation at compatible overhangs generated by BsaI.

Enhanced FusX assembly using an automated liquid-handling laboratory automation tool. (A) OT-One liquid-handling robot (LHR) set up for TALEN (transcription activator-like effector as nuclease) arm assembly via the FusX system. The MacBook laptop (1) operates the graphical user interface of the LHR software running on a Raspberry Pi 2 (RPi) single-board computer. (2) The RPi takes the JSON script of an arbitrary protocol and parses it into a G-code job to be run by the Smoothieboard numerical controller. (3) A monitor connected to the RPi via HDMI to visualize the RPi OS (GNU/Linux 8.0). (4) LHR workspace. (B) DRAGONLAB 10-μl micropipette. (C) Zoom-in on LHR workspace. Black border: six 96-well plates containing the libraries FusX1–4, Fus_B2+B3, and an extra plate (M) with the receiver backbone plasmid and the pLR plasmid stocks. White border: 10-μl tip rack (R), trash bin (T), and destination aliquots for TALEN arm assembly (Q). (D) Organization of the FusX 96-well plates. In black, all 64 possible combinations of RVD array plasmids were arranged on the basis of the output from the Mojo Hand inventory-management software for TALEN arm assembly for libraries FusX1–4 and Fus_B3. In gray, the 16 extra wells for plasmids of the Fus_B2 library in the pFusB2+B3 plate.

Using the FusX system to assemble custom TALENs in a single reaction. Dotted arrows indicate assembly at the compatible 5′ and 3′ overhangs generated with BsmBI.

Quality control of TALEN assembly, using colony PCR and restriction enzyme digestion. (A) Representative colony PCR using primers TAL_F1/TAL_R2. Correct colonies (+) result in characteristic laddering due to the repetitive nature of the incorporated RVDs. (B) Representative restriction enzyme digestion analyses with AatII/StuI are shown [these clones differ from those shown in (A)]. The size of the lower band is dependent on the number of TALE repeats within the TALEN, which can aid in determining correct clones. +, correct TALEN clones; *, incorrect TALEN clones.

In vivo mutagenic activity of TALEN pairs assembled with the FusX system. (A) Comparison of somatic efficiency between TALEN pairs (with identical RVD arrays) assembled via the FusX system (FLT3 P1X, P2X, and P3X) or via the original GGT method (FLT3 P1, P2, and P3). Average results of 3 separate experiments analyzing groups of 10 embryos are shown. Error bars represent the SEM, and efficiencies of TALEN pairs were statistically analyzed with unpaired t tests. (B) Somatic efficiencies of 30 TALEN pairs assembled with the FusX system. Error bars represent the SEM. Detailed descriptions of these TALEN pairs are found in Table 4. (C) Design of CHD P1 (TALEN 13) targeting zebrafish chordin Exon-1. (D) Embryos injected with CHD P1 (panel iii) showed significant ICM expansion (arrowhead) at 24 hr postfertilization (hpf) compared with wild type (panel i), phenocopying the morpholino-mediated chordin knockdown (panel ii).
Somatic activities and germline efficiencies of 30 TALEN pairs synthesized with FusX system
| 1 | NN NN NI NN NG NN NN HD NN NN NI NN NI NN NN | NN HD HD NG NI NG NN NI NI HD NG HD HD NG N | 10.6 ± 6.3% | 3/7 | |
| 2 | NI NG NI NI NI NG NG NI NG NI NI NG NN HD NI NN | NI NI NI NI NN NI HD NN HD HD NI NN NN HD HD NI | 13.1 ± 6.8% | 2/3 | |
| 3 | NG NN NG NG NN HD HD NN HD NG NN NG NN NN NI | NI NI NN NI NI HD NN NG NI HD HD NG NI NI NG | 14.5 ± 4.0% | 1/6 | |
| 4 | NI HD NG HD HD NI HD HD NI NN NG NN NG NN NN NI | HD NN NI NI NN NN NG NG HD HD NG NN NI NI HD | 15.6 ± 3.9% | 1/7 | |
| 5 | HD NI HD HD NI HD NI NN NI HD HD NG NN HD HD | HD HD NG HD NG HD NG NN HD NI HD HD NG HD NG | 27.2 ± 6.2% | 2/2 | |
| 6 | HD HD NI HD HD HD HD NG HD NI HD NI NG NG NI NN | NI NI NN NN NI HD NI NG NI HD NI NN NI NI HD NG | 31.6 ± 11.6% | N/A | |
| 7 | HD NG NI NN NI NN NG HD HD NI NN HD NI NN HD | HD NG NG HD NG NN NI NN HD HD HD NN HD HD NG HD | 37.8 ± 17.6% | 2/2 | |
| 8 | NI HD NI NG HD NI NN NN NG NI HD NG HD NG NN HD | HD NI NN NG NN HD NI NN HD HD HD NN HD NI HD NN | 38.7 ± 10.8% | 1/4 | |
| 9 | HD HD NG HD NN NN NI NN NN NI HD NI NN HD NG HD | NN NG HD HD NG NI HD NG HD NI NN HD HD NG NG NI | 39.3 ± 9.3% | 4/7 | |
| 10 | NI NI NI HD NI NI NI NI NN NI NN NI HD HD NG | NN HD HD NG NG NG NG HD NG NG HD NG HD HD NI | 44.5 ± 9.5% | 2/6 | |
| 11 | NG HD NN NG NN NG NN HD HD NN NN NG HD NN NN NG | NN HD NI NN HD NG NN HD NG NN NI NI NN HD HD HD | 46.2 ± 27.9% | 1/2 | |
| 12 | HD NI NI NI NN NI NN NI NI NN NN NI NN NI NI | HD NG HD HD NG HD HD NG NG NN HD NG NN NI NN NG | 47.2 ± 14.1% | 2/7 | |
| 13 | HD NN HD NI NG HD NG NN NG NN HD NI HD NN NN | NN NN NI NG NN NN NN HD NI NN HD NN HD NN NN | 48.2 ± 3.6% | N/A | |
| 14 | NG NG NN HD HD NG HD HD NI NG NN NI NG NI NG | HD NG HD NG NN NN NN NG NN NG HD NI NG NN NG | 49.5 ± 7.0% | N/A | |
| 15 | NG NG HD NG NG NG HD NN NG HD NG NG HD HD NI NN | NG NN NI NI NI NN HD NG NI NG NG NG NG NI NI | 55.9 ± 8.6% | 3/8 | |
| 16 | NG NI NN NG NN NG NN HD NI HD NG NG HD NG NN | NI HD HD NI HD HD NG NN NI NN NI NN NG NG NN | 56.3 ± 12.5% | 2/4 | |
| 17 | NN NN NI NN NN NI HD NI NN NI NN HD NN NG NI HD | HD NG HD HD NI NG NI NN NN HD NG NG HD HD NI | 59.2 ± 14.9% | 1/2 | |
| 18 | NG NN NG NN NI NG HD HD HD NG NG NI HD HD NN | HD NG NN NI NN NN NG NI HD NI NG NN NI NN NI | 61.1 ± 7.6% | 3/8 | |
| 19 | NG NG NN NN NN NI NI HD NI NI NN NI NG NN NN | NG NG NN HD HD NI NI HD NI NN NI NI NI NI NG | 66.7 ± 33.3% | 2/12 | |
| 20 | NG NG NN HD HD NI NI HD NI NN NI NI NI NI NG | HD HD NG NG HD NG NN HD NG NG HD NI NN NN HD NG | 70.9 ± 5.8% | 2/2 | |
| 21 | HD NG NN NG HD NG NN NI NN NN HD HD NN NN HD | NN NN NN NI NI NI NI NN NG NG NG NN NN NG NN NI | 79.2 ± 6.3% | 1/2 | |
| 22 | NI HD HD HD NI NN HD NI NI NN NI NN HD NG NG | NG NI NN NG NN NG NN HD NI HD NG NG HD NG NN | 80.3 ± 5.2% | 3/3 | |
| 23 | NG HD HD NG NN HD NI NN NN NI NN NN HD NN HD NG | NN NI HD NI NN NG HD NG NN NN NG NN NI HD HD | 87.0 ± 6.7% | 3/3 | |
| 24 | NN NG NG NI NG NN NG NI NG NG HD NI HD NN HD | NI HD HD HD NI NN HD NI NI NN NI NN HD NG NG | 88.8 ± 8.1% | 2/2 | |
| 25 | NN NG NI NI NN NI NG NN NN NG NI HD NI NI NG NG | NI NN NI NG HD NG HD HD NI NG HD NG NG HD NG NN | 89.1 ± 5.5% | 1/2 | |
| 26 | NN NN NG NI HD NN NI HD NI NN NN NG NG HD NI NN | NI HD HD NI NN NN HD NG HD NI NN NN HD NG NG | 90.4 ± 5.1% | 1/3 | |
| 27 | NI HD HD NI NN NN HD NG HD NI NN NN HD NG NG | HD NG NG NI NI NG NI NG NN HD NG HD HD NG HD NG | 91.8 ± 6.9% | 2/2 | |
| 28 | HD HD NN NI NI NN NI NI HD NG NN HD NI HD NG | NI NG HD NG NN HD HD NI NI NI NN NG NI NN HD | 91.8 ± 4.2% | 1/2 | |
| 29 | NI NG NI NN NN NN NI NN HD NN NG HD NI NG NN NN | NI NN NG NG HD NG HD HD NI NN HD NG NG HD NG | 98.8 ± 0.9% | 2/4 | |
| 30 | NG NI NG NG HD NI NN NI HD NN NG HD NI NN NN | NI NI NI NI NG HD NG NN NI NI NG NG NI HD NI HD | 99.0 ± 0.6% | 1/2 | |
In vivo somatic activities (percentage of NEHJ-mediated mutations at the somatic level, based on RFLP assay) and germline transmission efficiencies of 30 TALEN pairs synthesized with the FusX system. FLT P1X, P2X, and P3X are independent TALEN pairs targeting different regions of the flt3 gene, and somatic activities are determined by RFLP assay (n = 3) and presented with the SEM.
Germline efficiency is shown as the number of F0 that gave mutant offspring over the total number of F0 screened embryos.
N/A, not applicable as germline testing was not completed for these three TALEN pairs; RFLP, restriction fragment length polymorphism; RVD, repeat-variable diresidue; TALE, transcription activator-like effector; TALEN, TALE as nuclease.